ArticleCombinatorial chemistry & high throughput screening2026
Acupoint Catgut Embedding Alleviates Neuropathic Pain by Regulating Sigma-1 Receptor Expression.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAcupoint Catgut Embedding (ACE), also known as acupuncture catgut implantation, exerts analgesic effects by inhibiting Sig-1R. This study aimed to evaluate the modulatory effect of ACE on Sig-1R and its mechanism of action in alleviating nerve pain.
methodsWe assessed behavioral changes in mechanosensitive and thermosensitive pain in rats. Spinal cord tissue damage was examined using HE staining, while apoptosis was evaluated through TUNEL staining. Sig-1R expression in spinal cord tissue was analyzed via immunohistochemistry.
resultsACE and Sig-1R antagonists significantly reduced paw withdrawal frequency (PWF), decreased the expression of Bax and cleaved caspase-3 proteins, and alleviated morphological damage in spinal cord cells. They also increased the expression of Bcl-2 and prolonged paw withdrawal latency (PWL) in rats. Additionally, ACE and Sig-1R antagonists reduced levels of TNF-α, IL-1β, and IL-6, as well as malondialdehyde (MDA), while elevating levels of Superoxide Dismutase (SOD) and Glutathione Peroxidase (GPx) in both serum and spinal cord tissues. Furthermore, they downregulated the protein expression of p-ERK1/2, p38 MAPK, and Nox2, reduced the number of Th1 and Th17 cells, and increased the number of Th2 and Treg cells. DISCUSSION: Currently, the mechanism of action of ACE on neuropathic pain caused by peripheral nerve injury based on Sig-1R is still unclear. This study evaluated the mechanism by which ACE alleviates neuralgia by regulating the expression of Sig-1R in the spinal cord. In future work, we aim to conduct additional experiments to determine the precise localization of T cells within the spinal cord and to further investigate their direct interactions with glial cells.
conclusionACE effectively alleviates nerve pain by modulating Sig-1R expression in the spinal cord, thereby regulating inflammatory responses, oxidative stress, and associated signaling pathways.
Indexed as
Identifiers
40849735What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.